Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.42 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.42 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.42 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495412 | 0.87 | FFAR1 (0.49) | EPHX2APPFFAR1MAPTMEN1 | |
| SCHEMBL6484020 | 0.87 | CA1 (0.45) | EPHX2MAPTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6481682 | 0.87 | PPARA (0.44) | EPHX2FFAR1PPARA | |
| SCHEMBL7246584 | 0.84 | CYP1A2 (0.53) | MAPTCYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL6482295 | 0.84 | HPGD (0.54) | MAPTCYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL6480126 | 0.84 | SMN1; SMN2 (0.46) | EPHX2MAPTCYP2C19CYP3A4CYP2C9 | |
| SCHEMBL6491860 | 0.82 | KDM4E (0.49) | MAPTMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL6493823 | 0.82 | EGFR (0.50) | MAPTCYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL6493319 | 0.82 | HTT (0.53) | MAPTCYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL7245463 | 0.82 | MAOB (0.47) | MAPTCYP1A2CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | EPHX2 2079/4885APP 4080/4885FFAR1 4196/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | EPHX2 3805/4885APP 4742/4885FFAR1 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.